Table 4.
Baseline characteristics of ZONDA patients before and after adjusting to LIBERTY ASTHMA VENTURE patients for the analysis of mean percentage reduction in OCS dosage and percentage of patients with OCS elimination
| Characteristics | ZONDAa (before adjusting) | LIBERTY ASTHMA VENTURE (aggregate reported data) | ZONDA (after adjusting to LIBERTY ASTHMA VENTURE) |
|---|---|---|---|
| Benralizumab 30 mg Q8W + placebo N = 148b | Dupilumab 300 mg Q2W + placebo N = 210 | Benralizumab 30 mg Q8W SC + placebo ESS = 36 | |
| BMI, kg/m2 | 29.47 (6.06) | 29.34 (5.96) | 29.34 (3.66) |
| ACQ‐5 score | 2.67 (1.16) | 2.50 (1.16) | 2.5 (0.71) |
| Exacerbations in previous year | 2.82 (2.39) | 2.09 (2.16) | 2.09 (1.33) |
| OCS dosage adjusted at baseline, mg/d | 14.2 (7.05) | 11.26 (6.12) | 11.26 (3.76) |
| Blood eosinophil count, cells/µL | 592.22 (483.84) | 347 (307) | 347 (188.45) |
| Nasal polyps (%) | 32.39 | 33.80 | 33.81 |
Data presented as mean (SD) unless otherwise indicated.
Abbreviations: ACQ‐5: Asthma Control Questionnaire 5; BMI: body mass index; ESS: effective sample size; OCS: oral corticosteroid; Q2W: every 2 wk; Q8W: every 8 wk (first three doses every 4 wk); Abbreviation: SD, standard deviation.
a
Data for the ZONDA population are calculated from individual patient data.
b
One patient was missing a baseline blood eosinophil count; six patients were missing information on 100% OCS reduction.